Antibody Discovery News and Research

RSS

Turbine appoints new SAB members to guide its simulation-first drug discovery mission

Turbine appoints new SAB members to guide its simulation-first drug discovery mission

Turbine, a simulation-first drug discovery company, today announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.

21 Jan 2020

Integral Molecular announces panel of P2X7 antibodies for autoimmune disorders

Integral Molecular announces panel of P2X7 antibodies for autoimmune disorders

Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces lead monoclonal antibodies (MAbs) against P2X7, a structurally complex ion channel that is the target for autoimmune disorders including atopic dermatitis and glomerulonephritis.

10 Jan 2020

IONTAS, Adaptate Biotherapeutics join forces to generate and optimize antibodies for novel cancer targets

IONTAS, Adaptate Biotherapeutics join forces to generate and optimize antibodies for novel cancer targets

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.

From FairJourney Biologics 4 Dec 2019

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

The growing trend of implementing immunotherapy into oncology has resulted in various new therapeutic cancer treatments utilizing antibodies.

From Sartorius 3 Dec 2019

Sphere Fluidics and Peak Analysis and Automation introduce integrated micro-plate handling and single cell analysis capabilities

Sphere Fluidics and Peak Analysis and Automation introduce integrated micro-plate handling and single cell analysis capabilities

Sphere Fluidics and Peak Analysis and Automation, announce optimization of the Single Cell Analysis System through integration with automated plate handler.

From Sphere Fluidics 7 Nov 2019

We are excited to release our latest software update with new Cyto-Mine functionalities!

We are excited to release our latest software update with new Cyto-Mine functionalities!

The Cyto-Mine Studio Suite contains a collection of software to allow Cyto-Mine operation and data acquisition.

From Sphere Fluidics 16 Oct 2019

BioStreamline: Streamlining the development of next generation biotherapeutics

BioStreamline: Streamlining the development of next generation biotherapeutics

A collaboration to streamline the development of cost-effective next generation biotherapeutics will host a dissemination event at CPI.

From Sphere Fluidics 16 Oct 2019

Sphere Fluidics closes $2 million USD (c. £1.5 million GBP) investment round

Sphere Fluidics closes $2 million USD (c. £1.5 million GBP) investment round

Sphere Fluidics, announced that is has closed a $2 million (circa £1.5 million) investment round.

From Sphere Fluidics 16 Oct 2019

Sphere Fluidics collaborates with Peak Analysis and Automation to increase throughput in antibody discovery and cell line development

Sphere Fluidics collaborates with Peak Analysis and Automation to increase throughput in antibody discovery and cell line development

Sphere Fluidics, and Peak Analysis and Automation, will collaborate to offer automated micro-plate handling capabilities for single cell analysis.

From Sphere Fluidics 16 Oct 2019

The Scientist names Cyto-Mine technology #1 in the Top 10 Innovations of 2018

The Scientist names Cyto-Mine technology #1 in the Top 10 Innovations of 2018

We are delighted to announce that Cyto-Mine is one of the winners of The Scientist 2018 Top 10 Innovations!

From Sphere Fluidics 16 Oct 2019

Oxford Genetics unveils OXGENE brand

Oxford Genetics Ltd announces the launch of its brand OXGENE™. The new brand articulates the company’s powerful ability to combine highly innovative science with an engineering approach to custom solutions for biotechnology.

From OXGENE 11 Sep 2019

Rapid European adoption of Carterra’s LSA platform fuels expansion

Rapid European adoption of Carterra’s LSA platform fuels expansion

Carterra Inc., the world leader in high-throughput antibody screening and characterization, announced today that they have opened a Customer Experience Center and office in Munich, Germany. Rapid European adoption of Carterra’s platform has fueled the need for the new office.

From Carterra Inc. 16 Aug 2019

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

IONTAS Limited, a leader in antibody discovery and optimization of human monoclonal antibody libraries, today announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimization of human antibodies for use as biotherapeutics.

From FairJourney Biologics 31 Jul 2019

NIAID awards $22 million grant to develop antibody-based therapies against lethal viruses

NIAID awards $22 million grant to develop antibody-based therapies against lethal viruses

The National Institute of Allergy and Infectious Diseases has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.

4 Apr 2019

IONTAS wins 'Small Business of the Year' category at Cambridge News Business Excellence Awards 2019

IONTAS wins 'Small Business of the Year' category at Cambridge News Business Excellence Awards 2019

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has won ‘Small Business of the Year’ category at the Cambridge News Business Excellence Awards 2019.

25 Mar 2019

AvantGen and ACROBiosystems sign vendor agreement

AvantGen and ACROBiosystems sign vendor agreement

AvantGen Inc., a world-leading CRO for human and rabbit antibody discovery and optimization, and ACROBiosystems Inc., a global biotech company specializing in recombinant protein technology jointly announced the signing of a preferred vendor agreement between the parties.

From ACROBiosystems 7 Mar 2019

Sphere Fluidics announces closure of $2 million (circa £1.5 million) investment round

Sphere Fluidics announces closure of $2 million (circa £1.5 million) investment round

Sphere Fluidics announced today that is has closed a $2 million (circa £1.5 million) investment round.

From Society for Laboratory Automation and Screening (SLAS) 30 Jan 2019

Sphere Fluidics and PAA collaborate to offer automated micro-plate handling capabilities for single cell analysis

Sphere Fluidics and PAA collaborate to offer automated micro-plate handling capabilities for single cell analysis

Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation, a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis.

30 Jan 2019

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

Dr. John McCafferty celebrates the success of phage display technology with Nobel Prize in Chemistry Laureates.

From FairJourney Biologics 12 Dec 2018

Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics

Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics

Integral Molecular, the industry leader in the discovery of monoclonal antibodies against membrane proteins, and Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets.

12 Dec 2018

Previous
1
2
3
4
5
6
7
8
...
10
Next

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.